News Sentiment

PHVS sentiment intelligence

Pharvaris BV news scored across direct company coverage, industry context, sector read-through, source quality, and freshness.

Chart Weekly report Factors RSS feed
Weighted score 51 Balanced news tone 49 relevant articles
Exchange NASDAQ United States
Sector Healthcare Market context
Industry Biotechnology Read-through group
Latest close 34.94 Week of 17 Jul 2026
Weighted tone 51/100

Balanced news tone

Market reaction Balanced read

News tone and price action are not far from neutral.

Primary event Market update

83/100 classification confidence.

Company focus 40

directly relevant articles

Source quality 1

high-authority source matches

Trend context Trend active

-0.4% over one week, +6.5% over four weeks, trend active, and materially above fair value.

Latest direct headline Positive

Pharvaris publishes review on bradykinin B2 receptor research

Market Reaction

Balanced read

50/100 confidence

News tone and price action are not far from neutral.

Primary event Market update 83/100 classification
One-week reaction -0.4% Price digesting
Trend fit Trend active 6.5% over four weeks
Fair value 57.9% Materially above fair value

Sentiment Mix

Positive, neutral, negative

Weighted by relevance
Positive 11
Neutral 29
Negative 9

Relevance

Why the article matched

Direct first
Direct company coverage 40
Industry context 9
Sector context 0

Sources

Coverage mix

Publishers
Stock Titan 13
Market source 8
TradingView 6
simplywall.st 3
Finviz 3
Investing.com 2
Stock Traders Daily 2
MT Newswires 2

Event Lens

What the news is about

Classified themes
Market update 31
Earnings 12
Analyst action 4
Macro sensitivity 1
Balance sheet 1

Sentiment Trail

Score over time

50 baseline
Above 50 Neutral zone Below 50

News Tape

Relevant headlines

Showing 1-30 of 49
Investing.com Direct company coverage

Pharvaris publishes review on bradykinin B2 receptor research

Pharvaris (NASDAQ:PHVS) has published a review article in Clinical Reviews in Allergy & Immunology discussing the biology of bradykinin and the bradykinin B2 receptor. The article examines the scientific and clinical research supporting bradykinin B2 receptor antagonism as a ther

Tone
Positive 65/100
Event
Market update
Published
22 Jul 2026 11:19
Source
Investing.com
Stock Traders Daily Direct company coverage

(PHVS) Movement as an Input in Quant Signal Sets

This article analyzes Pharvaris N.v. (NASDAQ: PHVS) using AI models, identifying a weak near-term sentiment despite long-term strength. It outlines specific trading strategies including position, momentum breakout, and risk hedging, complete with entry points, targets, and stop l

Tone
Positive 66/100
Event
Market update
Published
20 Jul 2026 17:10
Source
Stock Traders Daily
Stock Titan Direct company coverage

Pharvaris (PHVS) CMO Lu Peng reports 226-share tax withholding event

Pharvaris N.V. Chief Medical Officer Lu Peng reported a tax withholding event involving 226 common shares at $35.07 per share. These shares were withheld to cover tax obligations arising from the vesting of restricted stock units. After this transaction, Lu Peng directly holds 65

Tone
Neutral 50/100
Event
Market update
Published
14 Jul 2026 19:47
Source
Stock Titan
Investing.com Nigeria Direct company coverage

Form 144 Pharvaris N.V. For: 13 July By Investing.com

Investing.com published a Form 144 filing for Pharvaris N.V. (PHVS) on July 13, 2026. This announcement indicates a notice of proposed sale of securities, although the specific details of the transaction are not provided in this brief update. The article provides the date of the

Tone
Neutral 50/100
Event
Market update
Published
13 Jul 2026 21:41
Source
Investing.com Nigeria
Stock Titan Direct company coverage

Pharvaris (PHVS) holder Berndt Modig files to sell 2,292 shares

Pharvaris (PHVS) shareholder Berndt Modig has filed a Form 144 to sell up to 2,292 shares of common stock, valued at approximately $80,380.44, through Morgan Stanley Smith Barney LLC on July 13, 2026. These shares are related to Restricted Stock Units dated July 11, 2026. The fil

Tone
Negative 40/100
Event
Market update
Published
13 Jul 2026 20:41
Source
Stock Titan
Contemporary Pediatrics Direct company coverage

FDA accepts deucrictibant IR application for on-demand treatment of hereditary angioedema attacks

The FDA has accepted Pharvaris'z NDA for deucrictibant IR, an oral bradykinin B2 receptor antagonist, for the on-demand treatment of hereditary angioedema (HAE) attacks. The PDUFA target action date is April 23, 2027. This acceptance is based on positive results from the Phase 3

Tone
Positive 73/100
Event
Earnings
Published
07 Jul 2026 06:41
Source
Contemporary Pediatrics
Stock Titan Direct company coverage

Pharvaris wins FDA review for oral HAE attack treatment

Pharvaris announced that the FDA has accepted its New Drug Application (NDA) for deucrictibant IR 20 mg capsules, an on-demand treatment for hereditary angioedema (HAE) attacks, setting a PDUFA target action date of April 23, 2027. The application is supported by data from over 1

Tone
Positive 93/100
Event
Analyst action
Published
06 Jul 2026 11:11
Source
Stock Titan
Finviz Direct company coverage

PHVS - Pharvaris NV Latest SEC Filings

This article provides a detailed financial overview and snapshot of Pharvaris NV (PHVS), a biotechnology company. It includes key financial metrics such as market cap, enterprise value, income, sales, various ratios, and performance indicators. The filing also lists insider and i

Tone
Neutral 50/100
Event
Market update
Published
03 Jul 2026 18:10
Source
Finviz
Finviz Direct company coverage

PHVS - Pharvaris NV Options

This article provides an overview of Pharvaris NV (PHVS) stock options and key financial data. It details market capitalization, enterprise value, income, sales, per-share metrics, profitability ratios, and various performance indicators. The data includes analyst recommendations

Tone
Neutral 50/100
Event
Analyst action
Published
03 Jul 2026 10:09
Source
Finviz
Finviz Direct company coverage

PHVS - Pharvaris NV Volatility & Greeks

This article provides an overview of Pharvaris NV (PHVS) financial metrics, including key statistics, performance indicators, and volatility measures as of July 2, 2026. It presents a snapshot of the company's market capitalization, income, sales, and various financial ratios, al

Tone
Neutral 50/100
Event
Market update
Published
02 Jul 2026 04:39
Source
Finviz
www.marketscreener.com Direct company coverage

Pharvaris Insider Sold Shares Worth $1,331,496, According to a Recent SEC Filing

An insider at Pharvaris N.V. (PHVS) sold shares worth $1,331,496, as reported in a recent SEC filing. This transaction, published on July 2, 2026, by MT Newswires, is part of several insider share disposals noted by MarketScreener for the biopharmaceutical company. Pharvaris focu

Tone
Negative 35/100
Event
Market update
Published
02 Jul 2026 04:22
Source
www.marketscreener.com
GuruFocus Direct company coverage

Insider Sell: Schikan Johannes Gerardus Christiaan Petrus Sells 37,600 Shares of Pharvaris NV (PHVS)

A director at Pharvaris NV (PHVS), Schikan Johannes Gerardus Christiaan Petrus, sold 37,600 shares of the company on June 30, 2026, reducing his holdings to 315,167 shares. This transaction is part of a pattern where the insider has sold a total of 80,000 shares over the past yea

Tone
Negative 30/100
Event
Market update
Published
02 Jul 2026 02:10
Source
GuruFocus
Stock Titan Direct company coverage

Pharvaris (PHVS) exec Lesage exercises options and sells 76K shares

Pharvaris N.V. executive Anne Lesage exercised options to acquire 37,572 shares and subsequently sold 76,172 shares of common stock at weighted average prices around $35 per share. These were pre-scheduled transactions under a Rule 10b5-1 trading plan, involving cashless exercise

Tone
Negative 35/100
Event
Market update
Published
01 Jul 2026 23:10
Source
Stock Titan
Stock Titan Direct company coverage

Pharvaris (PHVS) director sells 37,600 shares in Rule 10b5-1 plan

A director at Pharvaris N.V. (PHVS), Johannes Gerardus Christiaan Petrus Schikan, sold a total of 37,600 common shares in open-market transactions on June 29 and June 30, 2026, under a Rule 10b5-1 trading plan. The shares were sold at weighted average prices of $35.0533 and $35.4

Tone
Negative 34/100
Event
Market update
Published
01 Jul 2026 23:10
Source
Stock Titan
Stock Titan Direct company coverage

Form 144: Hans H. Schikan 10b5-1 sales listed for PHVS (PHVS)

A recently filed Form 144 for Pharvaris N.V. (PHVS) indicates proposed sales of Common shares linked to Founders Shares. The filing also details recent 10b5-1 sales by Hans H. Schikan, including transactions on June 29, 2026, for 6,888 shares valued at $241,447.13, and on April 3

Tone
Neutral 50/100
Event
Market update
Published
01 Jul 2026 04:10
Source
Stock Titan
Stock Titan Direct company coverage

PHVS (NASDAQ) insiders executed multiple 10b5-1 sales in 2026

PHVS insider Anne Simonne J. Lesage and Graymatters Consulting B.V. executed multiple pre-arranged 10b5-1 sales of Common stock throughout 2026, as detailed in a recent Form 144 SEC filing. These sales occurred on various dates, including 21,700 shares on April 30, 2026, and 8,30

Tone
Neutral 50/100
Event
Market update
Published
01 Jul 2026 04:10
Source
Stock Titan
Stock Titan Direct company coverage

PHVS insiders (PHVS) list option exercise and multiple 10b5-1 sales in June 2026

A recent SEC Form 144 filing indicates that insiders of Pharvaris N.V. (PHVS) have engaged in an option exercise and multiple pre-arranged 10b5-1 stock sales between April and June 2026. Key sellers include Anne Simonne J. Lesage and Graymatters Consulting B.V., with significant

Tone
Neutral 50/100
Event
Market update
Published
01 Jul 2026 04:10
Source
Stock Titan
Stock Titan Direct company coverage

PHVS (NASDAQ: PHVS) 10b5-1 sales logged; Form 144 for 6,888 shares

Pharvaris N.V. (PHVS) has filed a Form 144, indicating a proposed sale of 6,888 "Founders Shares" by an affiliated holder. The filing also details several past 10b5-1 sales executed by Hans H. Schikan, a company insider, on various dates in April and June 2026, totaling a signifi

Tone
Neutral 50/100
Event
Market update
Published
30 Jun 2026 03:39
Source
Stock Titan
Stock Titan Direct company coverage

Pharvaris (PHVS) CMO Lu Peng exercises options, sells 29,700 shares under 10b5-1 plan

Pharvaris N.V.'s Chief Medical Officer, Lu Peng, executed a pre-arranged sale of 29,700 shares of common stock on June 25-26, 2026, after exercising stock options at $2.59 per share. The shares were sold under a Rule 10b5-1 trading plan via cashless exercises, with weighted avera

Tone
Neutral 50/100
Event
Market update
Published
30 Jun 2026 03:39
Source
Stock Titan
Stock Titan Direct company coverage

Pharvaris (PHVS) exec’s 10b5-1 option exercise and 4,600-share sale

Pharvaris N.V. executive Anne Lesage, Chief Early Development, conducted a scheduled option exercise and sold a total of 4,600 common shares on June 25, 2026, under a Rule 10b5-1 trading plan. The sales, occurring at weighted average prices around $35.12 per share, were linked to

Tone
Negative 39/100
Event
Market update
Published
30 Jun 2026 03:39
Source
Stock Titan